Engmab Sarl

Hoffmann-la Roche Inc.

Bristol-myers Squibb Compnay

Engmab Ag

F. Hoffmann-la Roche Ag

Engmab Beta Holdings LLC

Samuel Moser

Christian Klein

Ekkehard Moessner

Pablo Umana

Ralf Hosse

Anne Freimoser-Grundschober

Oliver Ast

Minh Diem Vu

Marina Bacac

Wolfgang Schaefer

Lydia Jasmin Hanisch

Guy Georges

Joerg Thomas Regula

Pablo Umaña

Peter Bruenker

Thomas U Hofer

Michael Molhoj

Werner Scheuer

Claudia Ferrara Koller

Stefan Klostermann

Sandra Grau-Richards

Klaus Strein

Tanja Fauti

Juergen Michael Schanzer

Maria Amann

Christina Claus

Claudio Sustmann

Viktor Levitski

Rebecca Croasdale-Wood

Ramona Murr

Sabine Jung-Imhof

Tina Weinzierl

Lydia Jasmin Duerner

Camille Delon

Anne Freimoser-grundschober

The present invention relates to bispecific antibodies against ROR1 and CD3, their manufacture and use.

Bispecific antibodies against CD3EPSILON and ROR1

The present invention relates to bispecific HER2 antibodies, novel HER2 antibody variants, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Bispecific HER2 antibodies and methods of use

An antibody specifically binding to human BCMA, characterized in that the binding of said antibody is not reduced by APRIL and not reduced by BAFF, said antibody does not alter APRIL-dependent NF-&#x3ba;B activation, BAFF-dependent NF-&#x3ba;B activation, and does not alter NF-&#x3ba;B activation without BAFF and APRIL is useful as a therapeutic agent.

Method for the selection of antibodies against BCMA

The invention relates to new antibodies against BCMA, their manufacture and use.

Monoclonal antibodies against BCMA

A bispecific bi- or trivalent antibody specifically binding to the two targets which are extracellular domain of human B cell maturation antigen (BCMA) and human CD3&#x3b5;, wherein the variable domains VL and VH in a light chain and the respective heavy chain are replaced by each other, characterized in comprising a constant domain CL wherein the amino acid at position 124 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat), and in the respective constant domain CH1 the amino acid at position 147 and the amino acid at position 213 is substituted independently by glutamic acid (E), or aspartic acid (D) (numbering according to EU index of Kabat). Also the manufacture and use of said antibody.

Bispecific antibodies against CD3&#x3f5; and BCMA

A bispecific antibody specifically binding to the two targets human CD3&#x3b5; and human BCMA, wherein the variable domains of one antibody portion are replaced by each other, and characterized in that the binding of said antibody is not reduced by APRIL and not reduced by BAFF, said antibody does not alter APRIL-dependent NF-&#x3ba;B activation, BAFF-dependent NF-&#x3ba;B activation, and does not alter NF-&#x3ba;B activation without BAFF and APRIL is useful as a therapeutic agent.

Bispecific antibodies against CD3 and BCMA

Growing community of inventors

Rotkreuz, Switzerland

Samuel Moser